Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: A type I isobolographic analysis

Epilepsy Research

Volumn 89, Issue 2-3, 2010, Pages 207-219

  Luszczki, Jarogniew J ^a,b   Antkiewicz Michaluk, Lucyna ^c   Raszewski, Grzegorz ^b   Czuczwar, Stanislaw J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

1 Methyl 1,2,3,4 tetrahydroisoquinoline; Isobolographic analysis; Maximal electroshock; Pharmacodynamic pharmacokinetic interaction; Second generation antiepileptic drugs

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; ANTICONVULSIVE AGENT; LAMOTRIGINE; OXCARBAZEPINE; PREGABALIN; TOPIRAMATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ELECTRIC SHOCK; GRIP STRENGTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LONG TERM MEMORY; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; MUSCLE STRENGTH; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SEIZURE; TISSUE HOMOGENATE;

ANIMALS; ANTICONVULSANTS; AVOIDANCE LEARNING; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROSHOCK; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; MALE; MEMORY; MICE; SEIZURES; TETRAHYDROISOQUINOLINES; TRIAZINES;

EID: 77951297042     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.01.001     Document Type: Article

References (52)

1. Angehagen M., Ben-Menachem E., Shank R., Rönnbäck L., Hansson E. Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J. Neurochem. 2004, 88:320-325.
2. Antkiewicz-Michaluk L., Karolewicz B., Romanska I., Michaluk J., Bojarski A.J., Vetulani J. 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur. J. Pharmacol. 2003, 466:263-269.
3. Antkiewicz-Michaluk L., Lazarewicz J.W., Patsenka A., Kajta M., Zieminska E., Salinska E., Wasik A., Golembiowska K., Vetulani J. The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J. Neurochem. 2006, 97:846-856.
4. Antkiewicz-Michaluk L., Michaluk J., Mokrosz M., Romanska I., Lorenc-Koci E., Ohta S., Vetulani J. Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J. Neurochem. 2001, 78:100-108.
5. Antkiewicz-Michaluk L., Wardas J., Michaluk J., Romaska I., Bojarski A., Vetulani J. Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int. J. Neuropsychopharmacol. 2004, 7:155-163.
6. Boissier J.R., Tardy J., Diverres J.C. Une nouvelle methode simple pour explorer l'action «tranquilisante»: le test de la cheminee. Med. Exp. (Basel) 1960, 3:81-84.
7. Braga M.F., Aroniadou-Anderjaska V., Li H., Rogawski M.A. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J. Pharmacol. Exp. Ther. 2009, 330:558-566.
8. Brodie M.J., Schachter S.C. Fast Facts. Epilepsy 2001, Health Press, Oxford. 2nd ed.
9. Deckers C.L.P., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., Van Rijn C.M. Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia 2000, 41:1364-1374.
10. Dodgson S.J., Shank R.P., Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000, 41(Suppl. 1):S35-S39.
11. Gibbs J.W., Sombati S., DeLorenzo R.J., Coulter D.A. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000, 41(Suppl. 1):S10-S16.
12. Gryder D.S., Rogawski M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. 2003, 23:7069-7074.
13. Herrero A.I., Del Olmo N., Gonzalez-Escalada J.R., Solis J.M. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 2002, 42:210-220.
14. Ko G.Y., Brown-Croyts L.M., Teyler T.J. The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP, and GABA-IPSP in the rat hippocampus. Brain Res. Bull. 1997, 42:297-302.
15. Kotake Y., Taguchi R., Okuda K., Sekiya Y., Tasaki Y., Hirobe M., Ohta S. Neuroprotective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins. Brain Res. 2005, 1033:143-150.
16. Kotake Y., Tasaki Y., Makino Y., Ohta S., Hirobe M. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J. Neurochem. 1995, 65:2633-2638.
17. Kotake Y., Yoshida M., Ogawa M., Tasaki Y., Hirobe M., Ohta S. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate. Neurosci. Lett. 1996, 217:69-71.
18. Latini G., Verrotti A., Manco R., Scardapane A., Del Vecchio A., Chiarelli F. Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy. Mini Rev. Med. Chem. 2008, 8:10-23.
19. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96:99-113.
20. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953, 3:285-290.
21. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res. 2002, 50:105-123.
22. Löscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991, 8:79-94.
23. Luszczki J.J. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn-Schmiedebergs Arch. Pharmacol. 2007, 375:105-114.
24. Luszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J. 1-Methyl-1,2,3,4-tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model. Neuropharmacology 2006, 50:133-142.
25. Luszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J. Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol. 2009, 602:298-305.
26. Luszczki J.J., Borowicz K.K., Swiader M., Czuczwar S.J. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003, 44:489-499.
27. Luszczki J.J., Czuczwar M., Kis J., Krysa J., Pasztelan I., Swiader M., Czuczwar S.J. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003, 44:1003-1013.
28. Luszczki J.J., Czuczwar S.J. Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics-a comparative study. Epilepsy Res. 2003, 56:27-42.
29. Luszczki J.J., Czuczwar S.J. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn-Schmiedebergs Arch. Pharmacol. 2004, 369:434-446.
30. Luszczki J.J., Czuczwar S.J. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn-Schmiedebergs Arch. Pharmacol. 2006, 374:51-64.
31. Luszczki J.J., Ratnaraj N., Patsalos P.N., Czuczwar S.J. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Arch. Pharmacol. 2006, 373:169-181.
32. Luszczki J., Swiader M., Czuczwar M., Kis J., Czuczwar S.J. Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice. Pharmacol. Biochem. Behav. 2003, 75:319-327.
33. Luszczki J.J., Swiader M., Parada-Turska J., Czuczwar S.J. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 2003, 28:1817-1830.
34. Luszczki J.J., Wu J.Z., Raszewski G., Czuczwar S.J. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Arch. Pharmacol. 2009, 379:163-179.
35. Mathers D.A., Wan X., Puil E. Barbiturate activation and modulation of GABA(A) receptors in neocortex. Neuropharmacology 2007, 52:1160-1168.
36. Meyer O.A., Tilson H.A., Byrd W.C., Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav. Toxicol. 1979, 1:233-236.
37. Pietraszek M., Michaluk J., Romanska I., Wasik A., Golembiowska K., Antkiewicz-Michaluk L. 1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat. Neurotox. Res. 2009, 16:390-407.
38. Schmidt D. Modern management of epilepsy: rational polytherapy. Baillieres Clin. Neurol. 1996, 5:757-763.
39. Shank R.P., Doose D.R., Streeter A.J., Bialer M. Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Epilepsy Res. 2005, 63:103-112.
40. Shank R.P., Gardocki J.F., Streeter A.J., Maryanoff B.E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000, 41(Suppl. 1):S3-S9.
41. Tallarida R.J. Drug Synergism and Dose-effect Data Analysis 2000, Chapman & Hall/CRC, Boca Raton, USA.
42. Tallarida R.J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 2006, 319:1-7.
43. Tasaki Y., Makino Y., Ohta S., Hirobe M. 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J. Neurochem. 1991, 57:1940-1943.
44. Taverna S., Sancini G., Mantegazza M., Franceschetti S., Avanzini G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. 1999, 288:960-968.
45. Twyman R.E., Rogers C.J., Macdonald R.L. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann. Neurol. 1989, 25:213-220.
46. Vartanian M.G., Radulovic L.L., Kinsora J.J., Serpa K.A., Vergnes M., Bertram E., Taylor C.P. Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 2006, 68:189-205.
47. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., Rossier J. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 1986, 321:864-866.
48. White H.S., Brown S.D., Woodhead J.H., Skeen G.A., Wolf H.H. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000, 41(Suppl. 1):S17-S20.
49. White H.S., Smith M.D., Wilcox K.S. Mechanisms of action of antiepileptic drugs. Int. Rev. Neurobiol. 2007, 81:85-110.
50. Yamakawa T., Kotake Y., Fujitani M., Shintani H., Makino Y., Ohta S. Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci. Lett. 1999, 276:68-70.
51. Yamakawa T., Ohta S. Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci. Lett. 1999, 259:157-160.
52. Zhang X., Velumian A.A., Jones O.T., Carlen P.L. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000, 41(Suppl. 1):S52-S60.